Page last updated: 2024-08-21

indazoles and Orphan Diseases

indazoles has been researched along with Orphan Diseases in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baker, LH	1
Goozner, M	1

Other Studies

2 other study(ies) available for indazoles and Orphan Diseases

Article	Year
The necessity for rigour in rare disease study design. The Lancet. Oncology, 2019, Volume: 20, Issue:9 Topics: Drug Therapy, Combination; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Pyrimidines; Rare Diseases; Research Design; Sulfonamides; Vinblastine	2019
Drug approvals 2011: focus on companion diagnostics. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib	2012

Article

Year

The necessity for rigour in rare disease study design.

The Lancet. Oncology, 2019, Volume: 20, Issue:9

Topics: Drug Therapy, Combination; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Pyrimidines; Rare Diseases; Research Design; Sulfonamides; Vinblastine

2019

Drug approvals 2011: focus on companion diagnostics.

Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2

Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib

2012